Promis Neurosciences (PMN) Projected to Post Quarterly Earnings on Monday

Promis Neurosciences (NASDAQ:PMN) is expected to be issuing its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($1.06) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 9:30 AM ET.

Promis Neurosciences Stock Performance

Shares of NASDAQ PMN traded up $0.18 during trading hours on Monday, hitting $11.19. The company’s stock had a trading volume of 11,010 shares, compared to its average volume of 137,727. The stock has a market cap of $100.35 million, a price-to-earnings ratio of -0.59 and a beta of -0.20. Promis Neurosciences has a 12 month low of $6.27 and a 12 month high of $39.75. The business has a 50-day simple moving average of $15.84 and a 200-day simple moving average of $12.04.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Guggenheim cut their target price on Promis Neurosciences from $125.00 to $35.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Wall Street Zen cut Promis Neurosciences to a “strong sell” rating in a research note on Saturday, February 14th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Promis Neurosciences in a research note on Thursday, January 22nd. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Promis Neurosciences presently has a consensus rating of “Moderate Buy” and an average target price of $42.67.

Insiders Place Their Bets

In other Promis Neurosciences news, Director Eugene Williams bought 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were bought at an average cost of $24.00 per share, with a total value of $48,000.00. Following the completion of the purchase, the director directly owned 12,397 shares of the company’s stock, valued at $297,528. This trade represents a 19.24% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Patrick D. Kirwin acquired 4,000 shares of the business’s stock in a transaction on Wednesday, April 22nd. The shares were purchased at an average cost of $11.33 per share, for a total transaction of $45,320.00. Following the completion of the transaction, the director owned 4,653 shares in the company, valued at approximately $52,718.49. This represents a 612.56% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 709,370 shares of company stock valued at $8,640,843 over the last three months. Company insiders own 1.50% of the company’s stock.

Institutional Trading of Promis Neurosciences

A hedge fund recently raised its stake in Promis Neurosciences stock. Citadel Advisors LLC raised its position in shares of Promis Neurosciences (NASDAQ:PMN) by 168.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 170,079 shares of the company’s stock after acquiring an additional 106,650 shares during the quarter. Citadel Advisors LLC owned approximately 0.32% of Promis Neurosciences worth $72,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 50.13% of the company’s stock.

About Promis Neurosciences

Promis Neurosciences, Inc is a clinical?stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis.

Leveraging a proprietary small?molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation.